Recent Updates
Recently added Catalysts

Glucovance

Phase 3

Diabetes Mellitus, Non-Insulin-Dependent | Small molecule | Metabolic |Bristol-Myers Squibb Company|Last Updated: Apr 15, 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment -

FDA Designations

No designations recorded

Clinical trial landscape

Glucovance · 1 trial · 1 indication

Phase 3 1
NCT00035542A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.Diabetes Mellitus, Non-Insulin-Dependent
COMPLETED- Analytics
PHASE3COMPLETED
A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.
Diabetes Mellitus, Non-Insulin-Dependent
NCT00035542-
Unlock trial analytics

Study Design & Arms

PurposeTREATMENT

Interventions

NameTypeDescription
Glucovance (metformin HCl/glyburide)DRUG -
metformin HClDRUG -
glyburideDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range9 Years to 16 Years
SexALL
Healthy VolunteersNo
Study Sites50

Children ages 9-16 years with a diagnosis of type 2 diabetes mellitus who are not adequately controlled with diet and exercise, with or without oral hypoglycemic therapy, and have an HbA1c greater than 6.4%

Countries:United States
Unlock Eligibility Criteria